bluuebunny/crossref_metadata_2025_split huggingface dataset:
Acquired von Willebrand's Syndrome and Thrombopathy in a Patient with Chronic Lymphocytic Leukaemia
Authors: Wautier J. L. , Levy‐Toledano S. , Caen J. P. 
Published: August 2010

This paper reports the biological data found during an acquired bleeding disorder occurring in a 65‐year‐old woman affected with chronic lymphocytic leukaemia. They consists of haemostatic abnormalities which resemble an presently undescribed association of an acquired von Willebrand's syndrome with a thrombopathy.von Willebrand abnormalities were temporarily corrected by infusion of normal cryoprecipitate and reproduced in vitro by the incubation of normal platelets with the patient's IgA. The platelet defect was partially corrected after corticotherapy. The possible relationship of the associated defects is discussed.
Multiple Vacuoles Formation in Erythroblasts in an Erythroleukaemic Patient
Authors: Miura Akira B. 
Published: August 2010

Peculiar erythroblasts with multiple vacuoles were observed in the bone marrow of an erythroleukaemic patient.Some erythroblasts contained more than 80 vacuoles on a thin section. The contents of vacuoles were amorphous with low electron density. No transitional form from mitochondria or other organelles was observed. Since these vacuolated erythroblasts were clearly distinguishable from megaloblastoid erythraemia cells, multiple vacuoles formation is presumably attributable to the disturbance of microconnection net work in the normal red cell series.
Chromosome Studies in Untreated Polycythaemia Vera
Authors: WESTIN JAN , WAHLSTRÖM JAN , SWOLIN BIRGITTA 
Published: August 2010

Bone marrow chromosomes were studied in a series of 50 consecutive, unselected cases of untreated polycythaemia vera (PV). A pathological cell line was present in 7 patients (= 14%), 3 patients each had 1 extra chromosome no. 8 and 1 extra no. 9. 2 patients had a similar but not identical marker chromosome including material from the long arms of chromosome no. 1. 1 of these patients also had a 20q – deletion. 1 patient had an extra unidentified isochromosome. 1 patient had a monosomy 16. In 5 cases the abnormal clone dominated over cells with a normal karyotype. In each of 6 patients a singular hyperdiploid cell was observed. 1 or several polyploid or randomly hypodiploid cells were found in most patients.The findings in our material are compared to other reports of chromosome studies in PV and allied disorders. Except for the 20q – deletion no abnormality typical for PV has so far been detected, but some chromosomes seem to be involved more often than others (1, 8, 9, 20). Patients with chromosome aberrations did not show any clinical, laboratory or morphologic features which could separate them from cases with normal karyotypes. The prognostic significance of the chromosome abnormalities encountered in early PV cannot be defined at present.
Aplastic Anaemia with ‘Hot Pockets’
Authors: Kansu Emin , Erslev Allan J. 
Published: August 2010

4 patients with chronic severe aplastic anaemia and with persistent foci of intense haematopoietic activity, so‐called ‘Hot Pockets’, in their bone marrow were studied. In all patients the remainder of the bone marrow was morphologically and erythrokinetically hypoplastic. The cellular morphology in these ’Hot Pockets’ displayed megaloblastic features and definite maturation abnormalities in erythroblasts, but no consistent changes in the myeloid or megakaryocytic series.The presence of persistent ‘Hot Pockets’ presents a conceptual challenge since these pockets contain multipotential stem cells capable of differentiation and self‐renewal, but obviously incapable of repopulation of the bone marrow. In view of additional evidence for dyserythropoiesis in aplastic anaemia such as changes in erythroblast morphology and the production of macrocytes, fetal haemoglobin and complement sensitive cells, it seems likely that the bone marrow of aplastic anaemia patients is totally dyserythropoietic rather than hypoactive and that bone marrow transplantation in many cases may be both justified and necessary.
Confirmation of the Existence of Human Serum Leukaemia‐Associated Antigens (LAA)
Authors: Berg Käre , Stavem Per , Harris Rodney , Noer Grethe , Molne Käre 
Published: August 2010

We have obtained antisera from rabbits which react with serum from several leukaemia patients after absorption with normal human serum. The specificities of these rabbit antisera have been shown to be closely related to those of the original anti‐LAA antisera of Viza et al (1970) and Harris et al (1971). Thus, the existence of leukaemia associated (but probably not leukaemia specific) serum antigen in man has been confirmed.One of the animals was immunized with normal amniotic fluid obtained at 15–16 weeks of gestation. Thus, LAA seems to be a normal constituent of amniotic fluid. This suggests that LAA is another onco‐fetal component.
Spontaneous and Oxalate‐Induced Radial Segmentation of the Nuclei of Lymphocytes from Peripheral Blood from Patients with Chronic Lymphocytic Leukaemia
Authors: Valmin Klas 
Published: August 2010

Radial segmentation of nuclei of lymphocytes from peripheral blood from 18 patients with chronic lymphocytic leukaemia was studied in heparinized blood samples incubated with and without oxalate, for 6 h, at 20° C, and 37° C.The yield of radially segmented nuclei was the same after incubation at 20° C as at 37° C. Treatment with sodium oxalate resulted in an increased formation of radial segmentation to the same extent at 20° C as at 37° C.No correlation was found between the size of the lymphocytes and the frequency of radially segmented cells. The number of radially segmented nuclei did not vary with the WBC or Hb value. Cytostatic treatment with chlorambucil and cyclophosphamide did not inhibit the formation of radially segmented nuclei.
Splenectomy in Chronic Lymphocytic Leukaemia
Authors: Christensen B. Egelund , Hansen M. Mφrk , Videbæk Aa. 
Published: August 2010

In a retrospective study it was endeavoured to evaluate the effects of splenectomy in chronic lymphocytic leukaemia (CLL) characterised by splenomegaly. The material comprises 42 patients subjected to the operation in the course of the past 20 years. In the majority the spleen weighed more than 1000 g. The main indication for splenectomy was anaemia, while in 9 cases it was thrombocytopenia and in 14 cases hypercatabolism. Splenectomy is followed by a pronounced increase in the venous haemoglobin level and platelet count to higher values which have been recorded for up to 3 years after the procedure. In cases where data were available, there has been weight gain and a falling basal metabolic rate.Splenectomy is effective especially in cases predominated exclusively by splenomegaly, but even in cases with marked extrasplenic manifestations, splenectomy often greatly reduces the need for prednisone and cytostatics. Increasing hepatomegaly and lymphomas were not more common after splenectomy than in a control series, and the incidence of infections was not increased after the operation.For comparison, 37 non‐splenectomised patients with splenomegaly were assessed. X‐radiation of the spleen seems to be insufficient, since usually it has to be repeated. Splenomegaly does not decrease spontaneously and rarely after treatment with prednisone/cytostatics.The findings indicate that splenectomy of patients with CLL and increasing splenomegaly should be performed more often and presumably also earlier than recommended in the literature.
Toxicological Studies on Ferastral®, an Iron‐poly‐(sorbitol‐gluconic acid) complex
Authors: FLODH H. , MAGNUSSON G. , MALMFORS T. 
Published: August 2010

This paper presents a review of the toxicological studies in animals on Ferastral®, an iron‐poly (sorbitol‐gluconic acid) complex. Studies after single administration were performed in mice, rats and dogs, and LD50‐values were calculated in mice and rats. Studies after repeated administration were performed in rats and dogs. The test compound was given intramuscularly twice a week for five weeks to rats in doses varying from 50 to 400 mg Fe3+/kg, and to dogs from 5 to 200 mg Fe3+/kg. In a special study Ferastral was given intravenously to dogs every day for 12 days at the dose levels 5 and 20 mg Fe3+/kg. Imferon®, iron‐dextran, was used as a reference compound in some of the studies.Ferastral induced very little inflammatory reaction at the injection site. Depositions of iron‐containing pigments were found in all examined organs, being most pronounced at the intramuscular injection site, in the liver, spleen, and lymph nodes. Hyperplasia and hypertrophy as a reaction to the iron‐containing pigments resulted in increased weights of the liver and the spleen. Iron deposits in the liver occurred in both hepatocytes and Kupffer cells. With low doses the distribution was diffuse and with higher doses also focally accentuated. In both rats and dogs the focally accentuated distribution of iron in the liver was accompanied by granulomatous changes. There was a dose difference between rats and dogs. In rats iron was stored at the intramuscular injection site to a much greater extent than in dogs, and severe proliferation of iron‐loaded macrophages at the intramuscular injection site was seen in rats at much lower dose levels than in dogs. Imferon caused liver changes of similar appearance as those with Ferastral.
Oncological Study in Rats of Ferastral®, an Iron‐poly‐(sorbitol‐gluconic acid) complex, after Intramuscular Administration
Authors: MAGNUSSON G. , FLODH H. , MALMFORS T. 
Published: August 2010

Four groups of Sprague‐Dawley rats were given Ferastral®, an iron‐poly (sorbitol‐gluconic acid) complex (IPSG) or Imferon®, an iron‐dextran complex, intramuscularly twice a week for 17 weeks. The experiment lasted for 95 weeks. Each compound was given to two groups, one low dose group and one high dose group. Depending on the body mass, the dose levels varied between 2.5 and 10 mg (25—50 mg/kg body mass) and between 5 and 20 mg (50—100 mg/kg body mass) of iron per rat, respectively. The mean total dose of iron per rat was calculated to be 235 and 495 mg, respectively. Another group of animals served as a control.From about the 30th experimental week onwards tumours developed at the intramuscular injection sites in the groups given Ferastral and Imferon. The tumours appeared to be sarcomas. In almost all the treated animals that lived longer than 30 weeks after the start of the experiment, sarcomas were present at the intramuscular injection sites. The sarcomas appeared earlier in the high dose groups than in the low dose groups and slightly earlier in the rats given Ferastral than in those given Imferon. No other pathological changes, including neoplasms, were considered to be related to the treatment.
Absorption, Excretion, and Utilization of an Intramuscular Iron‐poly (sorbitol‐gluconic acid) complex, Ferastral®
Authors: BERESFORD C. H. , PALMER J. , KENNY M. W. 
Published: August 2010

An iron‐poly (sorbitol‐gluconic acid) complex (Ferastral®) labelled with59Fe was administered by intramuscular injection to clinically and haematologically normal male volunteers. Urinary excretion of radioactivity was measured for the first 48 hours following injection, and was 2%–10% of the administered dose. Disappearance of radioactivity at the site of injection and accumulation of radioactivity in the liver, spleen, and sacrum were measured by external scintillation counting.Plasma radioactivity was measured at intervals for four days and red cell incorporation of59Fe reached levels of 29%–57.5%. An unexpected finding was that the highest levels of urinary excretion of radioactivity did not coincide with the highest levels of plasma radioactivity.
Transfer of Iron from Ferastral® and other Organic Complexes to Transferrin as Measured by Reticulocyte Uptake
Authors: SPEYER BARBARA E. , DONEY VALERIE J. , FIELDING JACK 
Published: August 2010

The transfer of iron from the iron carbohydrate complexes, Ferastral®, Imferon®, and Jectofer®, and from ferric chloride has been studied by the effect of such transfer in reducing reticulocyte uptake of 59Fe from labelled transferrin. There are plasma factors which augment the transfer of iron from complex to transferrin.The pattern of transfer from Ferastral and from Imferon are similar: at concentrations of 5000 μg/100 ml and 1250 μg/100 ml in plasma these complexes transfer about 0.8% and 1.7%, respectively. Jectofer transfers about four times these amounts under similar conditions. In the case of Ferastral there is evidence of an equilibrium between transferrin‐bound and Ferastral‐bound iron.The characteristics of Ferastral assessed in this way suggest that it may prove suitable for therapeutic use as a total dose infusion.
Iron‐deficiency in the Tropics
Authors: Fleming A. F. 
Published: August 2010

Different populations in the tropics show wide variation in their iron status, even when living in the same area. These differences range from the most profound iron‐deficiency anaemia to nutritional haemosiderosis.The extremes of dietary iron content so far reported are 5 mg per day in Mauritius to 180 mg per day in Ethiopia. Contamination with inorganic iron is an important source in some communities. Generally, the iron in food is in excess of requirement, but lumenal factors are all important in deciding how much is available for absorption. The iron of some diets is readily absorbed, but in others only a small percentage is utilizable. Hookworm infection is the commonest cause of severe iron‐deficiency in many parts of the world. Its prevalence and its density depends on social habits, and may vary considerably even within tribes. The development of iron‐deficiency anaemia depends on the hookworm load being sufficient to cause iron loss in excess of available intake. Anaemia impairs work capacity, reproductive ability of women and the development of children, and has wide social and economic repercussions.An intramuscular preparation by which 500 mg of iron may be administered in one injection has most useful application in areas where medical care is minimal.
Side‐effects and Placental Function in Six Pregnant Women Treated with Ferastral®
Authors: Svanberg B. , Rybo G. 
Published: August 2010

A pilot study has been carried out with a new parenteral iron preparation, Ferastral®, in six pregnant women who had previously experienced side‐effects to oral iron. Patients were selected with only marginal anaemia and whose Hb‐concentration (10.3–12.4 g/100 ml) could be considered to be in the low normal range for pregnancy. Each patient received a total dose of 500 mg Ferastral, by the intramuscular route, but the single doses and times administration varied. In the study special attention was given to kidney and liver function, to placental function, and to side‐effects. At birth the infants were assessed by the Apgar score, and the placentae were examined both microscopically and macroscopically.At the initial Hb‐levels chosen and the Ferastral dose used, no significant changes were observed in Hb‐concentrations. Ferastral did not affect the values of the laboratory parameters of liver and kidney function studied. Placental function was unaffected, as shown by all oestrogen excretion values remaining within the normal range and the amount of estrogens increasing as expected as pregnancy progressed. Careful histological study showed no placental changes which could be related to Ferastral. In none of the infants were the Apgar scores less than 8.Concerning side‐effects, pain and discolouration at the site of the injection were observed in some cases.
The Treatment of Iron‐deficiency Anaemia with a New Intramuscular Iron Preparation (Ferastral®)
Authors: Ogunbode O. , Oluboyede O. A. , Ayeni O. 
Published: August 2010

The treatment of iron‐deficiency anaemia in pregnancy with a new intramuscular iron preparation, iron‐poly (sorbitol‐gluconic acid) complex (Ferastral®), has been assessed and compared with oral iron therapy. Sixty‐one of the eighty‐four patients studied, many of whom had mild to moderate degree of anaemia were treated with Ferastral. The results were satisfactory, the mean increase of haematocrit at the sixth post treatment week was 28.7% for the whole series. Complete correction of anaemia was achieved in most patients between the 4th and 6th week of treatment. The mean haematocrit of the group treated with oral iron was initially significantly higher than for the group treated with Ferastral. At the first follow‐up, two weeks after beginning treatment, the mean values for both groups were similar; at four weeks, those receiving Ferastral had a significantly higher mean PCV than those on oral iron, and remained so through the period of observation.No side‐effects were detected using 10 ml of Ferastral intramuscularly on alternate days. The mean hospitalization time of patients with severe to moderate anaemia was reduced when given parenteral therapy, and the frequency of blood transfusion in these patients was also decreased.
Syndrome of Shwachman and Leukaemia
Authors: Huijgens P. C. , van der Veen E. A. , Meijer S. , Muntinghe O. G. 
Published: August 2010

The syndrome of Shwachman is characterized by pancreatic insufficiency and bone marrow dysfunction, usually manifesting itself as neutropenia. The pancreas shows replacement of the exocrine glands by adipose tissue; sweat electrolytes are normal. A 23‐year‐old male who was known to suffer from neutropenia and pancreatic dysfunction from early childhood, presented with fever, acquired Pelger‐Huet anomaly (of the polymorphonuclear granulocytes) and sideroblastic anaemia, a combination of symptoms suggestive of preleukaemia. A few months later he died of acute myeloblasts leukaemia and autopsy showed a dystrophic pancreas.Considering this case history it seems possible that the haematological anomalies of Shwachman's syndrome are signs of preleukaemia. Careful follow‐up of patients suffering from Shwachman's syndrome seems warranted.
Light Green Crystals in May‐Grünwald and Giemsa‐Stained Bone Marrow Macrophages in Patients with Myeloid Leukaemia
Authors: Stavem Per , Ly Bernt , Bjørneklett Arvid 
Published: August 2010

A patient in a terminal stage of myelomocytic leukaemia had a number of elongated crystals in many bone marrow macrophages. The crystals were up to 20 micron long, showed a characteristic light green colour with May‐Grünwald & Giemsa, but did not stain with Sudan Black B or PAS. Electron microscopy showed that many of the crystals had a rhomboid form, but failed to show periodicity with the magnification used.A search was made for similar light green crystalline inclusions in patients with different types of leukaemia. Identical inclusions were found in 2 out of 5 other cases of myelomonocytic leukaemia, and in 3 out of 5 cases of chronic myeloid leukaemia. In contrast, such inclusions were not found in any of 6 patients with acute lymphoblastic leukaemia, nor in 4 patients with chronic lymphocytic leukaemia.
Pirimicarb Induced Immune Haemolytic Anaemia in Dogs
Authors: Jackson J. A. , Chart I. S. , Sanderson J. H. , Garner† R. 
Published: August 2010

The feeding of pirimicarb (2‐dimethylarnino‐5,6‐dimethylpyrimidin‐4‐yl dimethyl‐carbamate) to normal beagle dogs resulted in anaemia in a small number of animals.Dosing studies confirmed pirimicarb as the causative agent and the anaemia was characterised as haemolytic.Serological tests revealed the presence of an IgG antibody active only in the presence of pirimicarb. The level of antibody detected was related to the dose of pirimicarb given.
Complement Activation and Phagocytosis of Cryoglobulin Particles in a Patient with Plasma Cell Proliferative Disease
Authors: Stavem Per , Michaelsen Terje E. , Torsvik Harald , Rongved Gunnar 
Published: August 2010

The serum of a patient with a non‐aggressive plasma cell proliferative disorder contained two monoclonal immunoglobulins: IgG3λ in moderate concentration and having cryoglobulin features, and IgAκ in low concentration and without cryo‐precipitability.The patient's serum had low complement concentration and C3 was partly converted into split products in vivo. Complement (C3) together with cryoglobulin and fibrinogen was found by immunofluorescence in sections from skin showing vasculitis. The cryoglobulin particles which formed at room temp, were vividly phagocytized in vitro by neutrophile granulocytes from the patient and from normal individuals as demonstrated in light microscopy and ultramicroscopy.
Human Leukaemia Associated Antigen (LAA):
Authors: Berg K. , Noer G. , Stavem P. 
Published: August 2010

Serum leukaemia‐associated antigen (LAA) is identified as an oncofetal antigen (or antigens) since it is present in fetal liver and in amniotic fluid. Although it is mainly found in patients with proliferative haematological disorders, particularly acute leukaemias and chronic myelogenous leukaemia, LAA is occasionally present in sera from healthy people.In protein fractionation experiments, LAA behaves as a distinct population of molecules and has the characteristics of an α2‐β‐globulin, not carrying any lipids. The origin of LAA in haematological disorders is unknown. Its presence does not correlate with high white blood cell count, although antibody to LAA has been raised in animals injected with blast cells from leukaemia patients. LAA is distinct from α‐fetoprotein, and we have observed a reaction of immunolog‐ical non‐identity between LAA and ferritin. This is of considerable interest since ferritin has been reported to be immunologically closely related to α2H‐globulin which may occur in the same categories of patients as LAA. It is preliminary concluded that LAA as defined by our antisera may be different from α2H‐globulin and ferritin.
Experience on the Treatment of Chronic Myelocytic Leukaemia (CML) in Blastic Crisis
Authors: Mandelli F. , Amadori S. , Alimena G. , Annino L. , Nardelli S. , Papa G. 
Published: August 2010

A group of 50 patients with chronic myelocytic leukaemia in blastic crisis were treated with different chemotherapeutic regimens. A total of 19 remissions (6 CR + 13 PR) were achieved with an overall and complete response rate of 38 % and 12 % respectively. Of the 4 patients presenting with a lymphoblast‐like appearance of the blasts, the 3 treated with the combination of vincristine and prednisone all achieved remission (2 CR + 1 PR). Duration of survival was significantly longer in responding patients (median 11.5 versus 4.5 months).Either more effective therapeutic regimens or prevention by aggressively approaching the chronic phase are to be sought in order to improve the prognosis of blastic crisis of CML.
Detection of Anti‐Red Blood Cell Antibodies by Treatment of the Cells with Neuraminidase
Authors: Katz A. , Klajman A. , Yaretzky A. , Steiner Z. P. , Knyszynski Ahuva 
Published: August 2010

Neuraminidase treated RBC were used to detect incomplete unbound anti RBC antibodies in the plasma of patients with immune diseases. 80% (48 out of 60) of the examined patients gave positive results with this method while all the 50 normal normal controls were negative.The indirect antiglobulin test was negative in all the patients. In the direct antiglobulin test only two RBC samples, whether treated with neuraminidase or not, gave positive results.The present study indicates that the assay of plasma on neuraminidase treated RBC may serve as a sensitive method for the detection of the presence of anti RBC antibodies in various immunological diseases.